Global medical market research company, Ipsos Healthcare in May launched a syndicated study to highlight the impact of biosimilars on treating cancer patients.
Known as the Multi-Stakeholder Biosimilar Impact Study, it follows the firm’s successful launch of a 2014 syndicated Biosimilar Impact Study in the autoimmune field. The study has been developed in response to the ongoing launch of oncology biosimilars in the U.S. and European markets, and aims to support pharma and biotech companies in their strategic decision-making.
Rita Caldeira, Research Director, EU Oncology Monitor, said: “Given the ongoing introduction of biosimilars in oncology, it is critical to understand how these products will impact current treatment practices – both for manufacturers of branded biologic products and those developing biosimilar options. The study has already generated valuable insights in the autoimmune market.”